Chiron Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Emeryville CA United States (1981)
Status: Acquired by Novartis (2006)

Organization Overview

First Clinical Trial
1997
NCT00003126
First Marketed Drug
1992
aldesleukin (proleukin)
First NDA Approval
1992
aldesleukin (proleukin)
Last Known Activity
2006

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Biocine | CHIRON | Chiron company: Clinical Research and Medical Affairs | Chiron Corporation | Chiron s.r.l. Beijing Representative Office

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 1)

Adenocarcinoma (Phase 2)

Carcinoma, Renal Cell (Phase 4)

Colorectal Neoplasms (Phase 2)

Communicable Diseases (Phase 1)

Cytomegalovirus Retinitis (Phase 1)

Encephalitis (Phase 4)

Encephalitis, Tick-Borne (Phase 4)

Esophageal Neoplasms (Phase 2)

HIV Infections (Phase 2)

HIV Seropositivity (Phase 1)

Immunologic Deficiency Syndromes (Phase 1)

Infections (Phase 3)

Influenza, Human (Phase 3)

Kidney Neoplasms (Phase 4)

Leukemia (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Lymphoma (Phase 3)

Lymphoma, Non-Hodgkin (Phase 3)

Melanoma (Phase 2)

Meningitis (Phase 4)

Meningitis, Meningococcal (Phase 4)

Meningococcal Infections (Phase 4)

Neoplasms (Phase 2)

Rabies (Phase 2)

Retinitis (Phase 1)

Stomach Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 38
  • # of Trial APIs: 26